NCT00405938 - Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2011

Conditions

Breast CancerBreast Neoplasms

Interventions

DRUG

Bevacizumab

Bevacizumab 10mg/kg IV every 2 weeks

DRUG

Anastrozole

anastrozole (1 mg orally daily)

DRUG

Fulvestrant

fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).

Trial Locations (11)

30060

Wellstar Cancer Research, Marietta

30501

Northeast Georgia Medical Center, Gainesville

32256

Integrated Community Oncology Network, Jacksonville

32804

Florida Hospital Cancer Institute, Orlando

33901

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology & Hematology Associates, Chattanooga

42101

Graves-Gilbert Clinic, Bowling Green

59405

Sletten Cancer Institute, Great Falls

63017

St. Louis Cancer Care, Chesterfield

70806

Baton Rouge General Medical Center, Baton Rouge